Introduction
Somatic gene therapy represents a promising therapeutic option for genetic and acquired disorders of the immune system [1 . ]. Severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency was the first inherited disease treated with a gene transfer approach. This fatal syndrome is characterized by profound lymphopenia, impaired immune functions, recurrent infections, and systemic metabolic toxicity with alterations in nonlymphoid organs [2] [3] [4] [5] [6] . Allogeneic hematopoietic stem cell (HSC) transplantation from an HLA-identical sibling donor is an effective treatment, but the use of alternative donors is associated with elevated morbidity and mortality [7 . . ]. Weekly injections of bovine ADA conjugated to polyethylene-glycol (PEG-ADA) correct the metabolic defect but can result in suboptimal immune reconstitution, with a significant risk of developing neutralizing antibodies or autoimmunity [2] . Retroviral vectors derived from Moloney murine leukemia virus (MMLV) were considered optimal tools for gene therapy based on their safety record in preclinical studies, their ability to integrate into the chromosome of dividing cells, and to allow efficient expression of therapeutic genes into hematopoietic cells [1 . ]. The first gene therapy trials initiated in the early 1990s showed the safety, potential, and limitations of treating ADA-SCID patients with infusions of peripheral blood lymphocytes (PBLs) or hematopoietic progenitor cells [8] [9] [10] transduced ex vivo with retroviral vectors encoding the ADA gene. All the patients continued to receive injections of PEG-ADA which abolished the selective advantage provided by ADA gene transfer, allowing the survival and growth of defective lymphocytes in the presence of systemic detoxification. Similarly, in patients carrying 'naturally' corrected T cells due to spontaneous reverse mutations, the initiation of PEG-ADA caused a marked decrease in the proportion of corrected lymphocytes [2,11 . ]. Nevertheless, the experience and knowledge gained from these early studies was instrumental for the subsequent development of improved gene transfer protocols for ADA-SCID as well as other primary immunodeficiencies [12 . ,13 . ]. Here the authors will discuss the most recent advances in gene therapy for ADA-SCID using PBL and HSC gene therapy and the implications of these findings for future applications of gene transfer in other blood-borne disorders.
Gene therapy with peripheral blood lymphocytes
Based on the observation that patients receiving bone marrow transplant achieved immune reconstitution by sole engraftment of donor T cells, PBL gene therapy was proposed for the treatment of ADA deficiency in alternative or in combination with gene transfer in hematopoietic progenitors. Since the beginning of the first gene therapy trial in 1990, six ADA-SCID patients enrolled in three different protocols were treated with multiple infusions of transduced PBLs [8, 9, 14, 15 . . ,16 . ], while continuing to receive PEG-ADA. The three protocols used a similar retroviral backbone but differed for the mode of T cell activation, length of ex-vivo culture, and number of infused cells (reviewed in Aiuti [12 . ]) ( Fig. 1 ). Overall, a total of over 3 6 10 11 PBLs have been infused in the six patients with no adverse events or toxicity, with a follow-up extending from 6 to 12 years. In all patients, the integrated vector persisted long term after the treatment ended, with amelioration in immune functions, including increases in PBL counts and improved proliferative responses to mitogens and antigens.
Long-term persistence and adenosine deaminase expression of gene corrected peripheral blood lymphocytes
A recent report on the two children with the longest follow-up has provided important information on the survival of genetically corrected T lymphocytes in patients simultaneously receiving PEG-ADA [16 . ]. In the first treated patient, 10 years after the last cell infusion, 20% of the PBLs still contained vector ADA and expressed enzyme activity at approximately 25% of normal levels. By contrast, in the second patient the gene-marked cells persisted at very low levels, with no detectable expression of the transgene. This different outcome might be explained by the lower dose of infused transduced cells received (15 times less) compared with the first patient. Additionally, a persisting 
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The procedure for engineering mature lymphocytes (1) involved an activation step with polyclonal stimuli (2), followed by repeated transduction with the retroviral vector encoding the adenosine deaminase (ADA) gene (3) . After a variable period of culture, cells were cryopreserved and subsequently administered in repeated infusions (4) . Transduced lymphocytes expressing ADA persisted long-term in the peripheral blood of patients (5) . NK, natural killer; SV, SV40 promoter; neo, neomycin phosphotransferase.
antibody response was detected in the second patient to both the lipoprotein component of the fetal calf serum used in culturing lymphocytes [17] , as well as to an envelope protein of the vector (MMLV-p30), likely causing the elimination of infused cells [16 . ]. In both patients, PBL cell counts remained within normal range for 5 years after gene therapy, and thereafter started to slowly decline. Study of the T cell repertoire revealed in the first patient an expansion of a T cell population carrying a specific T cell receptor Vb family, with an altered distribution of the corresponding complementary-determining region. A monoclonal expansion was ruled out, since this skewed population was already present before gene therapy and molecular studies showed that it contained multiple different vector integration sites. The children remained healthy and did not suffer from severe infections or adverse events [16 . ]. In spite of the immunological and clinical improvement observed in these and other patients, however, the long-term clinical benefit impact remained difficult to assess because the children continued to receive PEG-ADA, even if at a reduced dose.
The impact of PEG-ADA discontinuation on peripheral blood lymphocyte gene therapy
Despite the strong rationale for discontinuing PEG-ADA in gene therapy studies, the decision to withdraw a potentially beneficial treatment was ethically challenging. Scientific and ethical conditions for attempting PEG-ADA discontinuation were met in a patient who during enzyme replacement therapy failed to sustain immune responses and showed clinical features of immune imbalance [15 . . ]. The rationale for removal of PEG-ADA was to favor the growth of PBLs carrying the normal ADA gene, with the final goal to restore normal immune functions. Indeed, following PEG-ADA discontinuation and intensification of infusions of engineered PBLs, transduced cells became the large majority of circulating T cells in this patient. This resulted in the correction of the ADA enzymatic activity in T cells, the normalization of in-vitro proliferative responses to polyclonal and allogeneic stimuli, and the production of specific antibodies after vaccination with a neoantigen [15 . . ]. In addition, peripheral blood T cell counts increased to values significantly higher than those observed during PEG-ADA treatment at full dosage, although still below the normal range. Remarkably, the T cell receptor Vb repertoire of circulating PBLs remained polyclonal and the profile of retroviral integration showed multiple different integrations. As expected, purine toxic metabolites accumulated in red blood cells in the weeks following discontinuation of PEG-ADA. However, toxic metabolites persisted during the follow-up, at levels higher than those observed in ADA-SCID patients receiving HSC transplantation, likely because of the suboptimal number of gene corrected T lymphocytes producing normal ADA. As a consequence, B lymphocytes, which are highly sensitive to toxic metabolites, decreased in the circulation, and serum immunoglobulin levels were reduced. Nevertheless, after cessation of the enzyme replacement therapy, the patient was free from severe infections, had a normal development, and an amelioration of dysregulated immune functions observed in association with PEG-ADA administration (asthma, eczema, elevated IgE) was observed [15 . . ]. In summary, this study showed that infusion of gene corrected PBLs was sufficient to restore normal T cell functions, but highlighted the need for better approaches, including ADA gene transfer into multipotent, long-living HSCs.
Gene therapy with hematopoietic stem/ progenitor cells
Since the design of the first gene therapy trials, HSCs have been considered the optimal target cells for longterm, full correction of the ADA-SCID defect. The early gene therapy studies showed that retroviral mediated transfer of the ADA gene into autologous bone marrow [8] or umbilical cord blood [10] progenitors was feasible, and resulted in engraftment of genetically corrected cells, with differentiation into multiple lineages [8, 10] . However, the proportion of transduced cells within both the HSCs and the mature blood cell compartment were insufficient for achieving ADA expression at therapeutic levels. A recent study has re-evaluated by clonal analyses of proviral integrants the number of genetically modified progenitors giving rise to mature T lymphocytes [18 . ] in one patient treated after birth with infusion of umbilical cord blood CD34 + cells. Results of this study showed that the majority of genetically modified T lymphocytes originated from a single, prethymic, transduced stem or progenitor cell, persisting from 9 to 94 months after gene therapy [18 . ]. No signs of leukemic transformation were observed, and the transduced T lymphocytes carried a diverse T cell receptor repertoire. Since T lymphocytes have a long life span, these results likely reflect the initial engraftment of a small number of transduced progenitors, due to a low number of cells infused or inefficient gene transfer of long-lasting progenitor cells. Since all patients continued to receive PEG-ADA injections, gene corrected cells lacked a selective pressure for their growth and expansion. An attempt to discontinue enzyme replacement therapy in a patient treated with umbilical cord blood CD34 + cells resulted in an increased proportion of transduced T lymphocytes [10] . The occurrence of a progressive loss of immune functions and reappearance of opportunistic infections, however, likely because of insufficient ADA expression in lymphocytes and other blood cells, led investigators to reintroduce enzyme replacement therapy. Neo CD34 + cells were harvested and purified from the bone marrow (1) and prestimulated for 24 h in the presence of cytokines [19 . . ] (2). Subsequently, cells were transferred to retronectin-coated bags previously loaded with retroviral particles and further transduced twice, for a total culture period of 4 days (3). Before reinfusion of the gene corrected cells, the patients received busulfan from day -3 to -2, at a total dose of 4 mg/kg (4), representing 50% of the recommended dose used in hematopoietic stem cell transplant for severe combined immunodeficiency [7 . . ]. Transduced stem/progenitor cells engrafted in the bone marrow, giving rise to a multilineage progeny of ADA-expressing cells (5) , with correction of the metabolic and immune defect. ADA, adenosine deaminase; NK, natural killer; PEG-ADA, bovine ADA conjugated to polyethylene-glycol; TPO, thrombopoietin; SCF, stem cell factor.
infusions. Correction of the metabolic defect was demonstrated by sustained ADA expression in multiple lineages, which led to a progressive decrease in red blood cell toxic metabolites and a substantial amelioration of systemic toxicity. Both patients have remained clinically well and free from severe infections or adverse events, with normal growth and development [19 . . ]. In summary, these data show that gene therapy with engineered HSCs in patients receiving low-dose busulfan is efficacious in correcting both the immune and metabolic defect of ADA deficiency, in the absence of enzyme replacement therapy.
Treatment of SCID-X1 with gene transfer of the g-chain gene into bone marrow CD34 + cells has resulted in the development of normal T and NK lymphocytes, allowing restoration of immune responses, with proven clinical benefit. Without any previous cytoreductive treatment, however, bone marrow progenitors, B lymphocytes and other hematopoietic cells, which lack the selective advantage of T/NK cells in this disease, remained mostly untransduced [21 . . ]. Concerns on chemotherapy-associated toxicity had restricted the use of conditioning for the treatment of genetic disease, despite the evidence that a certain degree of HSC depletion was required to achieve an adequate level of multilineage gene marking in murine and large animal models. The results of the improved ADA-SCID trial suggest that a moderate conditioning can be safely administered to the patients, and favors the engraftment of gene corrected HSCs, resulting in a higher proportion of transduced myeloid cells and B lymphocytes. This concept is also supported by recent murine bone marrow transplant studies in which low-dose busulfan allowed high levels of donor chimerism and immunological tolerance to donor grafts [22 . ]. Four ADA-SCID patients have recently been treated with a different clinical protocol based on an improved gene transfer procedure for bone marrow CD34 + cells, without administering chemotherapy, and continuing PEG-ADA injections.
Results of the first year of follow-up showed low levels of engraftment of marked cells, even in the lymphoid lineage, with no significant immune improvements, thus confirming the requirement for a selective advantage for the engraftment and expansion of HSCs and their lymphoid progeny [23].
Safety considerations
The cumulative results of PBL gene therapy in ADA-SCID demonstrate the safety of administering genetically modified autologous T cells, considering the high number of infused transduced cells, their in-vivo longterm persistence and the prolonged period of observation. ]. Taken together, these data suggest that the risk of insertional mutagenesis due to retroviral mediated gene transfer in ADA-SCID remains low. Nevertheless, careful monitoring and appropriate safety testing will be required to assess the long-term safety of the ADA-SCID patients treated with engineered HSCs.
Conclusions
Since the beginning of the early gene therapy trials for ADA-SCID over a decade ago, substantial progress has been made in dissecting the role of genetically modified PBLs and HSCs in correcting the metabolic and immune defect of the disease. PBL gene therapy can restore normal T cell ADA activity and functions if a selective advantage for transduced cells is created upon removal of systemic detoxification. Limitations of PBL gene therapy include the inability to correct previously skewed T cell repertoire and to generate de-novo specificities [16 . ], as well as an insufficient correction of the systemic metabolic defect [15 . . ]. HSC-based gene therapy combined with nonmyeloablative conditioning allows sustained HSC engraftment at high levels, with correction of both the systemic metabolic and immune defect, in the absence of enzyme replacement therapy. A longer follow-up in a larger cohort of patients will be required to confirm the safety and efficacy of HSC gene transfer, before proposing gene therapy as the treatment of choice for ADA-SCID. In the mean time, considering the proven clinical benefit of HSC gene transfer, and the present limitations of alternative therapeutic approaches, gene therapy protocols for ADA-SCID should be continued and extended to other patients in demand of an efficacious treatment. In view of the relatively high levels of marking obtained in the myeloid and progenitor cell compartment, the use of nonmyeloablative conditioning might also be extended to gene therapy for other inherited and acquired diseases, including primary immunodeficiencies, HIV infection, disorders of red blood cells, or lysosomal storage diseases in which efficiently expressing the normal enzyme in transduced hematopoietic cells may amend the metabolic defect [1 . ].
